-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Since -X- _ O
human -X- _ B-Patient
immunodeficiency -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
HIV -X- _ I-Patient
) -X- _ I-Patient
-infected -X- _ I-Patient
individuals -X- _ I-Patient
are -X- _ O
at -X- _ O
increased -X- _ O
risk -X- _ O
of -X- _ O
severe -X- _ O
disease -X- _ O
from -X- _ O
pandemic -X- _ O
influenza -X- _ O
A -X- _ O
( -X- _ O
H1N1pdm09 -X- _ O
) -X- _ O
, -X- _ O
vaccination -X- _ O
was -X- _ O
recommended -X- _ O
as -X- _ O
a -X- _ O
prevention -X- _ O
strategy. -X- _ O
The -X- _ O
aim -X- _ O
of -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
was -X- _ O
to -X- _ O
evaluate -X- _ O
the -X- _ O
safety -X- _ O
, -X- _ O
immunogenicity -X- _ O
and -X- _ O
persistence -X- _ O
of -X- _ O
the -X- _ O
immune -X- _ O
response -X- _ O
after -X- _ O
vaccination -X- _ O
against -X- _ O
pandemic -X- _ O
influenza -X- _ O
A -X- _ O
( -X- _ O
H1N1pdm09 -X- _ O
) -X- _ O
with -X- _ O
an -X- _ O
adjuvanted -X- _ B-Intervention
vaccine -X- _ I-Intervention
in -X- _ O
human -X- _ B-Patient
immunodeficiency -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
HIV -X- _ I-Patient
) -X- _ I-Patient
-infected -X- _ I-Patient
adults -X- _ I-Patient
using -X- _ O
two -X- _ B-Intervention
single -X- _ I-Intervention
and -X- _ I-Intervention
two -X- _ I-Intervention
double -X- _ I-Intervention
doses -X- _ I-Intervention
. -X- _ O

METHODOLOGY -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
Open -X- _ O
label -X- _ O
, -X- _ O
randomized -X- _ O
trial -X- _ O
to -X- _ O
evaluate -X- _ O
the -X- _ O
immune -X- _ O
response -X- _ O
following -X- _ O
H1N1pdm09 -X- _ B-Intervention
vaccination -X- _ I-Intervention
in -X- _ O
HIV-infected -X- _ B-Patient
participants -X- _ I-Patient
compared -X- _ O
to -X- _ O
HIV-negative -X- _ B-Comparision
controls -X- _ I-Comparision
( -X- _ O
NCT01155037 -X- _ O
) -X- _ O
. -X- _ O
HIV-infected -X- _ B-Patient
participants -X- _ I-Patient
were -X- _ O
randomized -X- _ B-Intervention
to -X- _ I-Intervention
receive -X- _ I-Intervention
2 -X- _ I-Intervention
single -X- _ I-Intervention
( -X- _ I-Intervention
3.75 -X- _ I-Intervention
μg -X- _ I-Intervention
hemagglutinin -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ I-Intervention
2 -X- _ I-Intervention
double -X- _ I-Intervention
( -X- _ I-Intervention
7.5 -X- _ I-Intervention
μg -X- _ I-Intervention
hemagglutinin -X- _ I-Intervention
) -X- _ I-Intervention
doses -X- _ I-Intervention
of -X- _ I-Intervention
the -X- _ I-Intervention
vaccine -X- _ I-Intervention
, -X- _ I-Intervention
21 -X- _ I-Intervention
days -X- _ I-Intervention
apart. -X- _ I-Intervention
Controls -X- _ B-Comparision
received -X- _ I-Comparision
one -X- _ I-Comparision
dose -X- _ I-Comparision
of -X- _ I-Comparision
the -X- _ I-Comparision
vaccine. -X- _ I-Comparision
The -X- _ O
primary -X- _ O
endpoint -X- _ O
was -X- _ O
seroconversion -X- _ O
as -X- _ O
measured -X- _ O
by -X- _ O
hemagglutination -X- _ O
inhibition -X- _ O
assay. -X- _ O
Two -X- _ B-Patient
hundred -X- _ I-Patient
fifty -X- _ I-Patient
six -X- _ I-Patient
HIV-infected -X- _ I-Patient
participants -X- _ I-Patient
( -X- _ I-Patient
129 -X- _ I-Patient
and -X- _ I-Patient
127 -X- _ I-Patient
randomized -X- _ I-Patient
to -X- _ I-Patient
single -X- _ I-Patient
and -X- _ I-Patient
double -X- _ I-Patient
doses -X- _ I-Patient
, -X- _ I-Patient
respectively -X- _ I-Patient
) -X- _ I-Patient
and -X- _ O
71 -X- _ B-Comparision
HIV-negative -X- _ I-Comparision
controls -X- _ I-Comparision
were -X- _ O
enrolled. -X- _ O
Among -X- _ O
HIV-infected -X- _ B-Outcome
participants -X- _ I-Outcome
, -X- _ I-Outcome
seroconversion -X- _ I-Outcome
increased -X- _ I-Outcome
from -X- _ I-Outcome
46.7 -X- _ I-Outcome
% -X- _ I-Outcome
and -X- _ I-Outcome
51.7 -X- _ I-Outcome
% -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
first -X- _ I-Outcome
dose -X- _ I-Outcome
to -X- _ I-Outcome
77.2 -X- _ I-Outcome
% -X- _ I-Outcome
and -X- _ I-Outcome
83.8 -X- _ I-Outcome
% -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
second -X- _ I-Outcome
dose -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
vaccine -X- _ I-Outcome
using -X- _ I-Outcome
single -X- _ I-Outcome
and -X- _ I-Outcome
double -X- _ I-Outcome
doses -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
Participants -X- _ B-Outcome
aged -X- _ I-Outcome
> -X- _ I-Outcome
40 -X- _ I-Outcome
years -X- _ I-Outcome
showed -X- _ I-Outcome
higher -X- _ I-Outcome
seroconversion -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
younger -X- _ I-Outcome
participants. -X- _ I-Outcome
Seroconversion -X- _ B-Outcome
among -X- _ I-Outcome
HIV-infected -X- _ I-Outcome
women -X- _ I-Outcome
and -X- _ I-Outcome
those -X- _ I-Outcome
with -X- _ I-Outcome
nadir -X- _ I-Outcome
CD4 -X- _ I-Outcome
< -X- _ I-Outcome
200 -X- _ I-Outcome
cells -X- _ I-Outcome
/ -X- _ I-Outcome
mm -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
with -X- _ I-Outcome
double -X- _ I-Outcome
doses. -X- _ I-Outcome
Persistence -X- _ B-Outcome
of -X- _ I-Outcome
protective -X- _ I-Outcome
antibodies -X- _ I-Outcome
six -X- _ I-Outcome
months -X- _ I-Outcome
after -X- _ I-Outcome
vaccination -X- _ I-Outcome
was -X- _ I-Outcome
achieved -X- _ I-Outcome
by -X- _ I-Outcome
80 -X- _ I-Outcome
% -X- _ I-Outcome
and -X- _ I-Outcome
89.9 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
HIV-infected -X- _ I-Outcome
participants -X- _ I-Outcome
who -X- _ I-Outcome
received -X- _ I-Outcome
single -X- _ I-Outcome
and -X- _ I-Outcome
double -X- _ I-Outcome
doses -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
. -X- _ O

CONCLUSIONS -X- _ O
/ -X- _ O
SIGNIFICANCE -X- _ O
: -X- _ O
Our -X- _ O
results -X- _ O
support -X- _ B-Outcome
the -X- _ I-Outcome
recommendation -X- _ I-Outcome
of -X- _ I-Outcome
two -X- _ I-Outcome
double -X- _ I-Outcome
doses -X- _ I-Outcome
of -X- _ I-Outcome
adjuvanted -X- _ I-Outcome
H1N1pdm09 -X- _ I-Outcome
vaccine -X- _ I-Outcome
for -X- _ I-Outcome
HIV-infected -X- _ I-Outcome
individuals -X- _ I-Outcome
, -X- _ I-Outcome
particularly -X- _ I-Outcome
women -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
those -X- _ I-Outcome
aged -X- _ I-Outcome
> -X- _ I-Outcome
40 -X- _ I-Outcome
years -X- _ I-Outcome
or -X- _ I-Outcome
with -X- _ I-Outcome
nadir -X- _ I-Outcome
CD4 -X- _ I-Outcome
< -X- _ I-Outcome
200 -X- _ I-Outcome
cells -X- _ I-Outcome
/ -X- _ I-Outcome
mm -X- _ I-Outcome
( -X- _ I-Outcome
3 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
to -X- _ I-Outcome
achieve -X- _ I-Outcome
antibody -X- _ I-Outcome
levels -X- _ I-Outcome
that -X- _ I-Outcome
are -X- _ I-Outcome
both -X- _ I-Outcome
higher -X- _ I-Outcome
and -X- _ I-Outcome
more -X- _ I-Outcome
sustained. -X- _ I-Outcome
TRIAL -X- _ O
REGISTRATION -X- _ O
: -X- _ O
ClinicalTrials.gov -X- _ O
NCT01155037 -X- _ O

